{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-040521","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.164071+00:00","generated_at":"2026-06-04T05:58:56.723572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fortress Biotech 2023 rev $84.5M; net loss $(68.7)M; DFD-29 PDUFA Nov 4, 2024","bullets":["Record consolidated net revenue $84.5M in 2023, up from $75.7M in 2022; net loss $(68.7)M ($8.47/share) vs $(94.6)M ($15.97).","Cash $83.4M at Dec 31, 2023, down $97.6M YoY; raised ~$34.9M in 2023/early 2024 offerings.","FDA accepted DFD-29 NDA for rosacea; PDUFA date Nov 4, 2024; up to 4 NDA/BLA decisions in next 18 months.","Cosibelimab BLA received CRL in Dec 2023 (manufacturing only); resubmission expected for 2024 approval.","Journey Medical product net revenues fell to $59.7M from $71.0M; total net rev $79.2M (+7%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-040521","json":"https://secwatch.observer/filing/0001104659-24-040521.json","markdown":"https://secwatch.observer/filing/0001104659-24-040521.md","text":"https://secwatch.observer/filing/0001104659-24-040521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/0001104659-24-040521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/tm2410123d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:58:56.723572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"156404b0c08d59e499df5d4ae1e84e4515bde083","claim":"Fortress Biotech, Inc. reported the full year ended December 31, 2023 results: revenue Record consolidated net revenue of $84.5 million.","evidence_excerpt":"Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/0001104659-24-040521-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"Record consolidated net revenue of $84.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}